BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus physician’s choice in advanced metastatic breast cancer (MBC).
The additional sites include the Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven—both of which have 15 satellite locations. According to BriaCell, positive results from the pivotal Phase 3 study could lead to full approval and marketing authorization for Bria-IMT in patients with MBC.
In a statement, Giuseppe Del Priore, MD, MPH, CMO of BriaCell, commented, “Clinical investigator interest in our Phase 3 study has exceeded our expectations, which has significantly expanded patient access to our treatment. This strong engagement reflects both the urgent unmet medical need in MBC and the dedication of our clinical partners.”
